154 OÊı·ÏÌÔÏÔÁ›·, 14, 2 (2002)diation therapy for meibomian gland carcinoma [casereport]. Am J Ophthalmol 87: 206-9, 1979.77. Ide CH, Ridings GR, Yamashita T, Buesseler JA. Radiotherapyof a recurrent adenocarcinoma of the meibomiangland. Arch Ophthalmol 79: 540-4, 1968.78. Bartley GB, Garrity JA, Waller RR, et al. Orbital exenterationat the Mayo Clinic: 1967-1986. Ophthalmology96: 468–73; discussion 473-4, 1989.79. Nunery WR, Welsh MG, McCord CD Jr. Recurrence ofsebaceous carcinoma of the eyelid after radiation therapy[case report]. Am J Ophthalmol 96: 10-5, 1983.80. Khan JA, Grove AS Jr, Joseph MP, Goodman M. Sebaceouscarcinoma. Diuretic use, lacrimal spread, and surgicalmargins. Ophthal Plast Reconstr Surg 5: 227-34,1989.81. Ni C, Kuo PK. Meibomian gland carcinoma. A clinicopathologicalstudy of 156 cases with long-period follow-upof 100 cases. Jpn J Ophthalmol 23: 388-401,1979.82. Ginsberg J. Present status of meibomian gland carcinoma.Arch Ophthalmol 73: 271-7, 1965.83. Esmaeli B, Wang B, Deavers M, et al. Prognostic factorsfor survival in malignant melanoma of the eyelid skin.Ophthal Plast Reconstr Surg 16: 250-7, 2000.84. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage Iprimary cutaneous melanoma: comparison of excisionwith margins of 1 cm or 3 cm. N Engl J Med 318: 1159-62, 1988.85. Veronesi U, Cascinelli N. Narrow excision (1-cm margin).A safe procedure for thin cutaneous melanoma.Arch Surg 126: 438-41, 1991.86. Balch CM, Urist MM, Karakousis CA, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas(1 to 4 mm): results of a multi-institutional randomizedsurgical trial. Ann Surg 218: 262-9, 1993.87. Salopek TG, Slade JM, Marghoob AA, et al. Managementof cutaneous malignant melanoma by dermatologistsof The American Academy of Dermatology. II. Definitivesurgery for malignant melanoma. J Am AcadDermatol 33: 451-61, 1995.88. Mohs FE. Microscopically controlled surgery for periorbitalmelanoma: fixed-tissue and fresh-tissue techniques.J Dermatol Surg Oncol 11: 284-91, 1985.89. Cascinelli N, van der Esch EP, Breslow A, et al. Stage Imelanoma of the skin: the problem of resection margins.Eur J Cancer 16: 1079-85, 1980.90. Day CL Jr, Mihm MC Jr, Sober AJ, et al. Narrower marginsfor clinical stage I malignant melanoma [letter].N Engl J Med 306: 479-82, 1982.91. Reintgen DS, Cox EB, McCarty KS Jr, et al. Efficacy ofelective lymph node dissection in patients with intermediatethickness primary melanoma. Ann Surg 198:379-85, 1983.92. Turkula LD, Woods JE. Limited or selective nodal dissectionfor malignant melanoma of the head and neck.Am J Surg 148: 446-8, 1984.93. Mays S, Nelson B. Current therapy of cutaneous melanoma.Cutis 63: 293-8, 1999.94. de Takats PG, Williams MV, Hawdins R. Adjuvant therapyfor melanoma: how should we respond to high-doseinterferon? [review]. Br J Cancer 77: 1287-93, 1998.95. Chapman P, Parkinson D, Kirkwood J. Biologic therapy.In: Balch C, Houghton A, Sober A, et al, eds. CutaneousMelanoma. Philadelphia: Lippincott, 419-36,1998.96. Rogers GS, Voseburg E, Wazer DE. New approaches totreating advanced melanoma: adjuvant treatment ofhigh-risk primary melanoma and boron neutron capturetherapy. Semin Cutan Med Surg 16: 165-73,1997.97. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomisedtrial of interferon alpha-2a as adjuvant therapy in resectedprimary melanoma thicker than 1.5 mm withoutclinically detectable node metastases. Lancet 351:1905-10, 1998.98. Pehamberger H, Sayer HP, Steiner A, Kofler R, et al. Adjuvantinterferon alpha-2a treatment in resected primarystage II cutaneous melanoma. J Clin Oncol 16:1425-9, 1998.99. Kirkwood J, Strawderman M, Ernstoff M, et al. Interferonalpha-2b adjuvant therapy of high-risk resected cutaneousmelanoma: the Eastern Cooperative OncologyGroup Trial EST 1684. J Clin Oncol 14: 7-17, 1996.100. Hancock B, Harris S, Wheatley K, Gore M. Adjuvant interferon-alpha in malignant melanoma: current status.Cancer Treat Rev 26: 81-9, 2000.101. Gennari R, Bartolomei M, Testori A. Sentinel node localizationin primary melanoma: preoperative dynamiclymphoscintigraphy, intraoperative gamma probe,and vital dye guidance. Surgery 127: 19-25, 2000.102. Esmaeli B. Sentinel lymph node mapping for patientswith cutaneous and conjunctival malignant melanoma[review]. Ophthal Plast Reconstr Surg 2000;16:170–2.103. Jansen L, Nieweg OE, Peterse JL, et al. Reliability ofsentinel lymph node biopsy for staging melanoma. BrJ Surg 87: 484-9, 2000.104. Carlson GW, Murray DR, Greenlee R, et al. Managementof malignant melanoma of the head and neck u-sing dynamic lymphoscintigraphy and gamma probeguidedsentinel lymph node biopsy. Arch OtolaryngolHead Neck Surg 126: 433-7, 2000.105. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperativeradiolympho- scintigraphy improves sentinel lymphnode identification for patients with melanoma. AnnSurg 223: 217-24, 1996.106. Shiose S, Sakamoto T, Yoshikawa H, et al. Gene transferof a soluble receptor of VEGF inhibits the growthof experimental eyelid malignant melanoma. InvestOphthalmol Vis Sci 41: 2395-403, 2000.ªÂÙ¿ÊÚ·ÛË: ∫. ªappleÔÌappleÔÚ›‰Ë˜
AÓ·ÛÎfiappleËÛË∂appleÈ̤ÏÂÈ·: A. M¿ÓıÔ˜e-mail: amanthos@med.auth.grH ÂÁ¯Â›ÚËÛË ÙÔ˘ ηٷÚÚ¿ÎÙË Û ·ÛıÂÓ›˜appleÔ˘ ¤¯Ô˘Ó ˘appleÔ‚ÏËı› Û ‚ÈÙÚÂÎÙÔÌ‹¢. ¢ÂÚÂÎÏ‹˜, ¡. §¿ÏÏÔ˜, ∞. ∫ÔÛÎÔÛ¿˜∂ÈÛ·ÁˆÁ‹∏ ÂͤÏÈÍË Ù˘ ¯ÂÈÚo˘ÚÁÈ΋˜ Ùo˘ ˘·ÏoÂȉo‡˜Î·È ·˘Ù‹˜ Ùo˘ ·ÌÊÈ‚ÏËÛÙÚoÂȉo‡˜, Ì ÙȘ apple·ÓÙoÂÈ-‰Â›˜ ‚ÂÏÙÈÒÛÂȘ Î·È ÙËÓ ˆÚ›Ì·ÓÛË Ù˘ Û¯ÂÙÈ΋˜ ÂÌappleÂÈÚ›·˜,¤¯ÂÈ o‰ËÁ‹ÛÂÈ ÛÙËÓ ÂÊ·ÚÌoÁ‹ Ù˘ Û ¤Ó·Â˘Ú‡ Ê¿ÛÌ· ¯ÂÈÚo˘ÚÁÈÎÒÓ apple·ı‹ÛÂˆÓ Ùo˘ oappleÈÛı›-o˘ ÙÌ‹Ì·Ùo˜ Ùo˘ ‚oÏ‚o‡. ∏ ÌÂÙÂÁ¯ÂÈÚËÙÈ΋ ·Ó¿-appleÙ˘ÍË Ùo˘ ηٷÚÚ¿ÎÙË ÛÙo˘˜ ‚ÈÙÚÂÎÙoÌËı¤ÓÙ˜ ·-ÛıÂÓ›˜ Â›Ó·È ·Û‡ÁÎÚÈÙ· appleÈo Û˘¯Ó‹ Û ۯ¤ÛË ÌÂÙoÓ ˘applefiÏoÈappleo Ù˘ ›‰È·˜ ËÏÈΛ·˜ appleÏËı˘ÛÌfi. ∏ ·appleo˘-Û›· Ùo˘ ˘·ÏoÂȉo‡˜ ÂÈÛ¿ÁÂÈ È‰È·›ÙÂÚ˜ ‰ÈÂÁ¯ÂÈÚË-ÙÈΤ˜ ‰˘ÛÎoϛ˜ ÛÙËÓ ÂÁ¯Â›ÚËÛË Ùo˘ ηٷÚÚ¿ÎÙË,Á‡Úˆ ·applefi ÙËÓ ·ÓÙÈÌÂÙÒappleÈÛË ÙˆÓ oappleo›ˆÓ ¤¯o˘Ó ‰È-·Ù˘appleˆı› ‰È¿ÊoÚ˜ ·applefi„ÂȘ Î·È ¤¯o˘Ó appleÚoÙ·ı›·applefi appleoÏÏo‡˜ ÂȉÈΤ˜ ¯ÂÈÚo˘ÚÁÈΤ˜ Ù¯ÓÈΤ˜. OÛÎoapplefi˜ Ùo˘ apple·ÚfiÓÙo˜ ¿ÚıÚo˘ Â›Ó·È Ó· ÙȘ appleÂÚÈ-ÁÚ¿„ÂÈ Î·È Ó· ÙȘ Û¯oÏÈ¿ÛÂÈ.˘¯ÓfiÙËÙ· ηٷÚÚ¿ÎÙË ÌÂÙ¿·applefi p.p. ‚ÈÙÚÂÎÙÔÌ‹O ηٷÚÚ¿ÎÙ˘ ÌÂÙ¿ ·applefi p.p. ‚ÈÙÚÂÎÙoÌ‹apple·›ÚÓÂÈ Û˘Ó‹ıˆ˜ ÙË ÌoÚÊ‹ Ù˘ ·Ó¿appleÙ˘Í˘ ‹ Ù˘ Ù·-¯Â›·˜ Âappleȉ›ӈÛ˘ ÂÓfi˜ ‹‰Ë ˘apple¿Ú¯oÓÙo˜ apple˘ÚËÓÈÎo‡Î·Ù·ÚÚ¿ÎÙË.  ¤Ó· Û¯ÂÙÈο ÌÈÎÚfiÙÂÚo appleoÛoÛÙfiÂÌÊ·Ó›˙ÂÙ·È Û·Ó oapple›ÛıÈo˜ ˘appleoappleÂÚÈÊ·ÎÈÎfi˜ ηٷÚ-Ú¿ÎÙ˘. ∏ Û˘¯ÓfiÙËÙ· Ùo˘ apple˘ÚËÓÈÎo‡ ηٷÚÚ¿ÎÙˤ¯ÂÈ Î·Ù·ÁÚ·Ê› ÛÙo 8% ˆ˜ 80% (Sneed 1984, Smidy1987, Melberg 1995) ÙˆÓ ·ÛıÂÓÒÓ Î·È Ùo˘ oappleÈ-Ûı›o˘ ˘appleoappleÂÚÈÊ·ÎÈÎo‡ ÛÙo 4% ˆ˜ 34% (Mester1989). OÈ appleÚÒÙ˜ apple·Ú·ÙËÚ‹ÛÂȘ ·ÊoÚo‡Û·Ó appleÂÚÈappleÙÒÛÂȘ·Ó¿appleÙ˘Í˘ apple˘ÚËÓÈÎo‡ ΢ڛˆ˜ ηٷÚÚ¿ÎÙËÛ ·ÛıÂÓ›˜ appleo˘ ›¯·Ó ˘appleo‚ÏËı› Û p.p. ‚ÈÙÚÂ-ÎÙoÌ‹ ÁÈ· ·Ê·›ÚÂÛË appleÚoˆ¯ÚÈÎÒÓ ÌÂÌ‚Ú·ÓÒÓ. ∂apple›-Û˘, Û appleoχ ÌÂÁ¿Ïo ·ÚÈıÌfi Î·È Û¯Â‰fiÓ Ù·˘Ùfi¯Úo-Ó· ‰ËÌoÛȇıËÎ·Ó appleoÏϤ˜ ·Ó·ÊoÚ¤˜ Ì ı¤Ì· ÙËÓ·Ó¿appleÙ˘ÍË oappleÈÛı›o˘ ˘appleoappleÂÚÈÊ·ÎÈÎo‡ ηٷÚÚ¿ÎÙËÌÂÙ¿ ·applefi ‚ÈÙÚÂÎÙoÌ‹, Ì appleoÈΛϘ ÂӉ›ÍÂȘ appleo˘·appleo‰fiıËÎ·Ó ÛÙËÓ apple·Ú·ÙÂٷ̤ÓË ¤Á¯˘ÛË ˘ÁÚÒÓ ‹ÛÙ· ÂÓ‰o‚oÏ‚Èο ·¤ÚÈ· Î·È ÛÙËÓ ˘ÁÚ‹ ÛÈÏÈÎfiÓË, appleo˘appleoÏϤ˜ ÊoÚ¤˜ ¯ÚËÛÈÌoappleoÈo‡ÓÙ·È Û ·˘Ù¤˜ Ù˘ ηٷ-ÛÙ¿ÛÂȘ. ÕÏψÛÙÂ, Â›Ó·È appleÈ· Û‹ÌÂÚ· apple¤Ú· ·applefi ο-ı ·ÌÊÈ‚oÏ›· ÁÓˆÛÙfi, fiÙÈ Ë ÂÓ‰o‚oÏ‚È΋ (˘ÁÚ‹) ÛÈ-ÏÈÎfiÓË appleÚoηÏ› ηٷÚÚ¿ÎÙË Û fiÏo˘˜ Ùo˘˜ ¤ÌÊ·-Îo˘˜ ·ÛıÂÓ›˜ (Christiansen 1976, Leaver 1976, Faulborn1978, Michels 1984, Gasswell 1987, ∞ÏÂÍ·Ó-‰Ú›‰Ë˜ 1995).¤Ú· ·applefi Ù· ¢ڤˆ˜ appleÈ· ·Ó·ÁÓˆÚÈṲ̂ӷ appleÚo-·Ó·ÊÂÚı¤ÓÙ· ·›ÙÈ· Ùo˘ ÌÂÙÂÁ¯ÂÈÚËÙÈÎo‡ ηٷÚÚ¿-ÎÙË ÛËÌ·ÓÙÈÎo› appleÚo‰È·ıÂÛÈÎo› apple·Ú¿ÁoÓÙ˜ ıÂ-ˆÚo‡ÓÙ·È oÈ ·ÎfiÏo˘ıoÈ:1. ∏ ÌÂÁ¿ÏË ËÏÈΛ· (Ogura 1993).2. ∏ appleÚo¸apple¿Ú¯o˘Û· ıfiψÛË Ùo˘ Ê·Îo‡ (DeBustros 1998).3. ∏ ‰È¿ÚÎÂÈ· Ù˘ Âapple¤Ì‚·Û˘ (Novak 1984).4. ∏ Âapple·Ê‹ Ùo˘ Ê·Îo‡ Ì Ùo ‚ÈÙÚÂoÊ¿Áo(Blodi 1997).5. O ‰È·‚‹Ù˘ (Blankenship, Machemer 1984).6. ∏ ‰È·ÛÎÏËÚÈ΋ ÎÚ˘oappleËÍ›· (Helbing 1997).7. ∏ ˘„ËÏ‹ ‰È¯ÂÈÚËÙÈ΋ ÂÓ‰oÊı¿ÏÌÈ· apple›ÂÛË(Pesin 1991, Nakasawa 1993, Thompson 1995).Ùo˘˜ ËÏÈÎȈ̤Óo˘˜ ·ÛıÂÓ›˜ o ηٷÚÚ¿ÎÙ˘·˘Ùfi˜ ¤¯ÂÈ ÙËÓ Ù¿ÛË Ó· apple·›ÚÓÂÈ Î˘Ú›ˆ˜ ÙË ÌoÚÊ‹Ùo˘ apple˘ÚËÓÈÎo‡, ÂÓÒ ÛÙo˘˜ Ó¤o˘˜ ÙË ÌoÚÊ‹ Ùo˘ oapple›-ÛıÈo˘ ˘appleoη„ÈÎo‡ (Poliner 1991, Hakin 1993).∫·Ù¿ ηÓfiÓ· ÂÍÂÏ›ÛÛÂÙ·È appleoχ ·ÚÁ¿ ·ÏÏ¿ appleÚoo-‰Â˘ÙÈο Î·È appleoÏϤ˜ ÊoÚ¤˜ ηχappleÙÂÈ Î·È appleÂÚÈoÚ›˙ÂÈÙËÓ ‚Ú·‰Â›· ‚ÂÏÙ›ˆÛË Ù˘ oappleÙÈ΋˜ ÏÂÈÙo˘ÚÁ›·˜ appleo˘OÊı·ÏÌÔÏÔÁ›·, 14, 2 : 155 - 160, 2002 155
- Page 5 and 6: ¯fiÏÈÔO Û‚·ÛÙfi˜ K·ı
- Page 7 and 8: OphthalmologiaContentsVolume 14 - N
- Page 9 and 10: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 11 and 12: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 13 and 14: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 15: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 19 and 20: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 21 and 22: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 23 and 24: ∫ÏÈÓÈΤ˜ Î·È ÂÚÁ·Û
- Page 25 and 26: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 27 and 28: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 29 and 30: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 31 and 32: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 33 and 34: ‡ÁÎÚÈÛË Ù˘ 24ˆÚ˘
- Page 35 and 36: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 37 and 38: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 39 and 40: ∏ ¯Ú‹ÛË Ù˘ ·ÏÏ·ÓÙ
- Page 41 and 42: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 43 and 44: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 45 and 46: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 47 and 48: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 49 and 50: OÊı·ÏÌÈο ÙÚ·‡Ì·Ù·
- Page 51 and 52: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 53 and 54: OappleÙÈ΋ o͇ÙËÙ·, ‰
- Page 55 and 56: OÊı·ÏÌÔÏÔÁ›·, 14, 2 (20
- Page 57 and 58: ∂ӉȷʤÚÔÓÙ· appleÂ
- Page 60 and 61: 198 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 62 and 63: 200 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 64 and 65: 202 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 66 and 67:
204 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 68 and 69:
‡ÌÌÂÈÎÙ·∂appleÈ̤ÏÂ
- Page 70 and 71:
208 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 72 and 73:
O ÔÊı·ÏÌfi˜ οÙÔappleÙ
- Page 74 and 75:
212 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 76 and 77:
214 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 78 and 79:
·ıÔÁ¤ÓÂÈ· Ù˘ ˘appleÂ
- Page 80 and 81:
218 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 82 and 83:
220 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 84 and 85:
222 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 86 and 87:
224 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 88 and 89:
226 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 90 and 91:
228 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 92 and 93:
230 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 94 and 95:
232 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 96 and 97:
234 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 98 and 99:
236 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 100 and 101:
238 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 102 and 103:
240 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 104 and 105:
242 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 106 and 107:
244 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 108 and 109:
246 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 110 and 111:
248 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 112 and 113:
ÂÚÈÏ‹„ÂȘ ·applefi ͤ
- Page 114 and 115:
252 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 116 and 117:
254 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 118 and 119:
256 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 120 and 121:
BÈ‚ÏÈÔÎÚÈÛ›·¡ÈÎfiÏ
- Page 122 and 123:
260 OÊı·ÏÌÔÏÔÁ›·, 14, 2
- Page 124:
Eȉ‹ÛÂȘ∂appleÈ̤ÏÂ